Clinical Trial Detail

NCT ID NCT02506959
Title Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

myeloid neoplasm

plasmacytoma

plasma cell neoplasm

Therapies

Dexamethasone

Busulfan + Melphalan

Pyridoxine

Panobinostat

Palifermin

Gemcitabine

Age Groups: adult

No variant requirements are available.